Fig. 6

Evaluation of treatment responsiveness for high group scores patients. Compared to the low- risk group, patients with high group scores showed significantly lower IC50 to treatment drugs docetaxel (A), ERK_6604 (B), Gefitinib (C), Luminespib (D), Sapitinib (E), SCH772984 (F), WIKI4 (G). (H, I) Showed that the high group scores more sensitive to immune checkpoint inhibitors, for PD1.